USA – MASSACHUSETTS Trends and Developments Contributed by: Patti Melick, Toby Bannon, Katherine Rubino and Kelsey Loomis, Wiggin and Dana LLP
aging risk while preserving innovation incentives. For transactional practitioners and industry participants alike, the next phase of growth in cell and gene ther- apy will depend as much on disciplined execution and creative structuring as it does on the science itself. Rare Disease Among the landscape of financial strain, selective dealmaking, and a new administration overhauling the regulatory and drug approval process in 2025, fed- eral and state agencies played a key role in shaping new pathways to advance innovation to support rare disease research and accelerate development frame- works for high need patient populations. In 2025, the FDA announced new regulatory pathways designed to accelerate treatments for rare disease , specifying essential criteria needed for approval. These pathways aimed to streamline the requirements and loosen evidentiary support providing a valuable advantage for companies navigating the complexities of seeking drug approval for rare indications. This new legislation demonstrated the disproportionate chal- lenges faced by small patient populations. By offer- ing a more predictable regulatory approval process, companies can pursue high impact programmes with greater confidence. Additionally, the NIH complemented the FDA approach to rare disease by supporting research to advance genetic disorders, autoimmune rare diseases, and novel therapeutic mechanisms. Initiatives supported by the NIH ranged from creating a brain-computer interface to decode inner speech for patients suffer- ing from brain injuries to using gene editing to support babies born with rare diseases and administering an experimental small molecule to alleviate Co-enzyme q10 deficiency. In a landmark move, the NIH made one of its largest, rare disease investments to date, providing USD26 million to the Rare Disease Clinical Research Net- work (RDCRN). This funding strengthened collabora- tive research groups aimed at bringing new therapies closer to patients. In Massachusetts, a robust advocacy infrastructure strengthened the local rare disease community. With
changes to orphan drug incentives and shifts in FDA leadership, organisations such as the Massachu- setts Rare Disease Advisory Council (RDAC) and the National Organization for Rare Disorders (NORD) pro- vided guidance, engagement, and support for innova- tors and patients alike. Their presence offered a sta- bilising force to ensure that even as federal signals fluctuated, local stakeholders retained a clear voice and reliable framework for advancing rare disease. In conclusion, the FDA’s expanded regulatory path- ways and the NIH’s substantial rare disease invest- ments reshaped the industry’s strategic landscape and offered alternative routes aimed at sustaining innovation in some of the most vulnerable of patient groups. Final Remarks As the life sciences industry moves into 2026, the industry is entering a time of renewed momentum and excitement. Venture capital is being deployed to drive innovation and growth and many therapeutic areas are poised for disruption. The demand for anti-aging and longevity treatments along with cardiometabolic treat- ments show no sign of slowing down. Radiopharma- ceuticals are attracting investment along with CAR-T therapies, which demonstrate a renewed interest in the oncology sector. Beyond scientific progress, 2026 will also be impacted by several high impact policy developments. Ongo- ing impacts from the 2025 Federal Circuit Decision of Regents of the Univ. of Cal. v Broad Inst., Inc. will be felt by life sciences companies as the Patent Trial and Appeal Board (PTAB) takes up the case on remand in view of new guidance from the Federal Circuit in regard to conception and reduction to practice of an invention. At the same time, many are awaiting review of Gilead Life Sciences v Superior Court being heard by the Cali- fornia Supreme Court, raising the “duty to innovate” issue and questions about pharmaceutical companies’ obligations to pursue new therapies as well as ques- tions about product liability and drug pricing. 2026 is shaping up to be a year of acceleration, growth, investment and a regulatory environment that will impact the life sciences industry for years to come.
423 CHAMBERS.COM
Powered by FlippingBook